MRVI250117P2500
- 0.00
- 0.000.00%
Maravai LifeSciences Newsroom
Guggenheim Initiates Maravai LifeSciences(MRVI.US) With Hold Rating
Maravai Lifesciences Initiated With a Neutral at Guggenheim
Danaher, Cryoport, Sartorius Win Buy as Guggenheim Expands Bioprocessing Coverage
Guggenheim Initiates Coverage on Maravai Lifesciences With Neutral Rating
Express News | Maravai LifeSciences Holdings Inc - Co's Unit Pre-Paid $228 Million of Term Loan
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
Maravai LifeSciences Appoints New Chairman Amid Leadership Transition
Maravai LifeSciences: Carl Hull to Retire as Executive Chairman >MRVI
Express News | Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Press Release: Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
4 Analysts Have This To Say About Maravai LifeSciences
Goldman Sachs Downgrades Maravai LifeSciences(MRVI.US) to Sell Rating
Goldman Sachs Downgrades Maravai Lifesciences to Sell From Neutral, Cuts Price Target to $4.25 From $7
Co-Founder & Executive Chairman of Maravai LifeSciences Holdings Carl Hull Buys 174% More Shares
Maravai LifeSciences Initiated at Peer Perform by Wolfe Research
Maravai LifeSciences Analyst Ratings
Wolfe Research Initiates Maravai LifeSciences(MRVI.US) With Hold Rating
Estimating The Fair Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Maravai LifeSciences | 10-Q: Q3 2024 Earnings Report